New drug combo shows promise for tough skin cancers

NCT ID NCT06624475

First seen Jan 31, 2026 · Last updated May 14, 2026 · Updated 16 times

Summary

This study tests whether a combination of two immunotherapy drugs (Opdualag) works better than one drug (nivolumab) alone for people with high-risk basal cell carcinoma that can be surgically removed. About 30 participants will receive treatment before surgery to see if the cancer shrinks or disappears. The goal is to improve outcomes and reduce the need for extensive surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California, Irvine

    RECRUITING

    Irvine, California, 92868, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California, San Diego Moores Cancer Center

    RECRUITING

    La Jolla, California, 92093, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94158, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.